Cisplatin-Teva concentrate for solution for infusion 0.5 mg/ml 100 ml — Made in Hungary — Free Delivery

Possible nephrotoxic effect (in 28–36% of patients), manifested by an increase in the level of residual nitrogen, creatinine, an increase in the concentration of uric acid and a decrease in creatinine clearance; myelosuppression (in 30% of cases), manifested by leukopenia and thrombocytopenia, anemia; manifestations of neurotoxicity - peripheral neuropathies (usually occurring after 4–7 months of treatment), which in some patients may be irreversible, as well as impaired taste sensations, convulsions; ototoxicity phenomena - in 31% of patients. usually ototoxicity is manifested by tinnitus, hearing loss in the high frequency range (4000-8000 Hz). the ototoxic effect of cisplatin in children is manifested more often and is more pronounced than in adults, especially after repeated administration of the preparation. hearing impairment can be unilateral or bilateral. the ototoxic effect of the preparation is more pronounced in patients who have previously been exposed to brain irradiation or receive radiation therapy simultaneously with the introduction of cisplatin. development of optic neuritis, edema of the nipple of the optic nerve and transient blindness are also possible; after the abolition of cisplatin, there is an improvement and / or complete restoration of vision. when using cisplatin in high doses, blurred vision and impaired color perception can be observed, especially in the yellow-blue spectrum. when examining the fundus, uneven retinal pigmentation is found in the area of ​​the optic spot. the majority of patients receiving cisplatin develop nausea and vomiting, which are sometimes so severe that they require discontinuation of the preparation. these symptoms usually occur within 1–4 hours after administration of the preparation and persist for 24 hours. nausea and anorexia may occur within a week after administration of cisplatin. high doses of metoclopramide are used to prevent vomiting caused by cisplatin. during treatment with cisplatin, there may be a decrease in resistance to infections, prolongation of wound healing and bleeding of the gums, and the development of stomatitis. the preparation has angio- and cardiotoxic properties, especially when combined with other antineoplastic agents; development of myocardial infarction, stroke, thrombosis of small vessels, Raynaud's syndrome is possible. the use of cisplatin may be accompanied by the development of hypomagnesemia, hypocalcemia, hyponatremia, hypokalemia and hypophosphatemia, probably caused by impaired renal tubular function. in patients with hypocalcemia and hypomagnesemia, tetanic seizures may occur, an increase in the level of iron in the blood plasma, the development of hyperuricemia and a change in the content of antidiuretic hormone. in patients with hypersensitivity to the preparation, anaphylactic reactions sometimes occur. in rare cases, phlebitis caused by intravenous administration of cisplatin is observed. there have been several cases of soft tissue necrosis during extravasation of cisplatin. IV infusion of cisplatin can cause pain, swelling and hyperemia at the injection site. possible anorexia, increased activity of serum transaminases, skin rash, alopecia.

Treatment with cisplatin can only be performed by an experienced chemotherapist in a specialized hospital. during and after treatment, it is necessary to control the composition of peripheral blood, the functional state of the liver and kidneys. the maximum decrease in the number of platelets and leukocytes is observed between the 18th and 23rd days, in most patients, the normalization of these indicators is noted by the 39th day of treatment. the nephrotoxic effect of the preparation is more pronounced during repeated courses of chemotherapy. reduction of nephrotoxicity of the preparation is achieved by intravenous hydration and forced diuresis with the use of mannitol. before starting treatment and before each subsequent course, it is necessary to determine the concentration of creatinine in the blood plasma, creatinine clearance, the level of residual nitrogen, magnesium, calcium, potassium and sodium.

With the development of anaphylactic reactions, the infusion of the preparation should be stopped immediately, corticosteroids, antihistamines should be prescribed, and the BCC should be corrected.

Cloudy solutions, as well as solutions containing sediment, are unsuitable for use.

The preparation is a potential embryotoxic, teratogenic and mutagenic agent. Breastfeeding should be discontinued during preparation treatment.

When working with the preparation, medical personnel should use protective clothing (gloves, gown), as well as glasses and a mask. In case of contact with eyes or mucous membranes, rinse with plenty of running water or isotonic sodium chloride solution. Pregnant women should not be allowed to work with the preparation.